Actively Recruiting
Evaluating Rozanolixizumab Compared to Placebo for Treating Adults With Ocular Myasthenia Gravis in a Randomized, Double-Blind Study
Led by UCB Biopharma SRL · Updated on 2026-10-27
120
Participants Needed
29
Research Sites
7 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy, safety, and tolerability of rozanolixizumab compared with placebo in adult participants with Ocular Myasthenia Gravis. This Phase 3 randomized, double-blind, placebo-controlled study aims to better understand how rozanolixizumab affects symptoms and quality of life in adults living with this eye muscle weakness condition. Participants will be randomly assigned to receive either rozanolixizumab or a placebo through subcutaneous infusion during a 6-week intervention period. After completing the treatment phase, participants enter a 4 to 7 week observation period, during which they may have the opportunity to join an open-label extension study. Throughout the trial, participants will be closely monitored for changes in ocular symptoms and any adverse events. During the study, participants will undergo regular assessments including patient-reported outcome measures focused on ocular symptoms, quality of life, and activities of daily living. Researchers will also evaluate physical examination findings of eye muscle weakness. Safety will be monitored by tracking treatment-emergent adverse events up to 13 weeks. Overall participation may last several months, including screening, treatment, observation, and possible extension phases.
CONDITIONS
Brief Title
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Research Team
U
UCB Cares
U
UCB Cares
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here